The overall goal of our Protocol Leadership Group (PLG) is to produce first-ever evidence on the effectiveness of a proven pragmatic lifestyle intervention targeted at modest, clinically meaningful weight loss and increased physical activity in overweight or obese patients with spirometry-confirmed COPD. In the 18-month simple, pragmatic clinical trial (PCT), we efficiently focus on the intervention effects primarily on weight loss and exercise tolerance; and secondarily on dyspnea, generic health-related quality of life (HRQoL) and cardiovascular risk factors (CVRFs).
|Effective start/end date||8/1/16 → 6/30/18|
- University of Pittsburgh (9012549(130129-21)//5U01HL128954-03)
- National Heart, Lung, and Blood Institute (9012549(130129-21)//5U01HL128954-03)